I reduce insulin resistance and may also decrease glucose production. I am used as an adjunct to diet and exercise to improve glycemic control. I am usually well tolerated and most common side effects are upper respiratory tract infection, headache, sinusitis and myalgia. I go by the name of pioglitazone (Actos). What class of oral hypoglycemic am I ?

A. Bile-acid sequestrants, such as colesevelam, primarily lower serum cholesterol levels. While they may have a modest effect on glucose levels, they do not directly improve insulin sensitivity or significantly reduce hepatic glucose production, which are the main mechanisms of pioglitazone.

B. Thiazolidinediones (TZDs), including pioglitazone (Actos) and rosiglitazone, are oral hypoglycemic agents used for type 2 diabetes mellitus. They work by activating peroxisome proliferator-activated receptor gamma (PPAR-γ) receptors in adipose, muscle, and liver tissue. This leads to enhanced insulin sensitivity, improved glucose uptake in peripheral tissues, and modest reduction in hepatic glucose production. TZDs are used as adjuncts to diet and exercise to improve glycemic control. They are usually well tolerated, with common side effects including upper respiratory tract infection, headache, sinusitis, and myalgia. However, nurses should monitor for weight gain, fluid retention, edema, and signs of heart failure, which are rare but serious adverse effects.

C. Alpha-glucosidase inhibitors (e.g., acarbose, miglitol) work by slowing carbohydrate absorption in the small intestine to reduce postprandial hyperglycemia. They do not improve insulin sensitivity or reduce hepatic glucose production, so they are mechanistically different from TZDs.

D. Non-insulin injectable drugs, such as GLP-1 receptor agonists (e.g., liraglutide, dulaglutide), are injectable agents that enhance glucose-dependent insulin secretion, slow gastric emptying, and promote satiety. Pioglitazone is an oral agent, not an injectable.